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Abstract
Metabotropic glutamate receptors (mGluRs) are normally expressed in the central nervous system, where they mediate
neuronal excitability and neurotransmitter release. Certain cancers, including melanoma and gliomas, express various
mGluR subtypes that have been implicated as playing a role in disease progression. Recently, we detected metabotropic
glutamate receptor-1 (gene: GRM1; protein: mGluR1) in breast cancer and found that it plays a role in the regulation of cell
proliferation and tumor growth. In addition to cancer cells, brain endothelial cells express mGluR1. In light of these studies,
and because angiogenesis is both a prognostic indicator in cancer correlating with a poorer prognosis and a potential
therapeutic target, we explored a potential role for mGluR1 in mediating endothelial cell (EC) proliferation and tumor-
induced angiogenesis. GRM1 and mGluR1 were detected in various types of human ECs and, using mGluR1-specific
inhibitors or shRNA silencing, we demonstrated that EC growth and Matrigel tube formation are dependent on mGluR1
signaling. In addition, loss of mGluR1 activity leads to reduced angiogenesis in a murine Matrigel sponge implant model as
well as a murine tumor model. These results suggest a role for mGluR1 in breast cancer as a pro-angiogenic factor as well as
a mediator of tumor progression. They also suggest mGluR1 as a potential new molecular target for the anti-angiogenic
therapy of breast cancer.
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Introduction
Angiogenesis is critical for normal physiological processes,
including wound healing, embryonic development, and the
menstrual cycle. Tumors are also critically dependent upon their
ability to hijack the normal physiologic process of angiogenesis and
thereby induce the ingrowth of blood vessels from the host in order
to grow, invade, and metastasize [1,2]. The process of angiogen-
esis is normally tightly regulated through control of the relative
levels of pro- and antiangiogenic factors, a process that has been
described as the ‘‘angiogenic balance’’ [3,4]. However, malignant
cells can shift the angiogenic balance away from homeostasis
towards angiogenesis through the secretion of proangiogenic
factors, the most common of which is VEGF [5], a peptide growth
factor secreted by a wide variety of cancers, beginning early in
progression [6]. Numerous studies have reported a correlation
between increased angiogenesis and poor prognosis in various
cancers [7,8], and inhibiting tumor-induced angiogenesis has
emerged over the last decade as a promising strategy for cancer
therapy. Indeed, the combination of antiangiogenic therapy with
conventional therapies, in particular radiation therapy and
cytotoxic chemotherapy, has led to significant increases in overall
survival in certain cancers such as colorectal cancer metastasis to
the liver [9]. However, antiangiogenic therapy is not without its
drawbacks. For example, bevacizumab, a humanized mouse
monoclonal antibody to VEGF that is currently the most
commonly used antiangiogenic therapy for cancer, is expensive,
must be given intravenously, and produces side effects of
hypertension, hemorrhage and even intestinal perforation, among
others [10,11]. In addition, tumors can overcome bevacizumab by
producing more VEGF, leading to resistance. [11].
Of the downstream mediators of VEGF receptors, PKC is
known to be a crucial mediator [12,13]. In a previous study,
Riluzole, a known inhibitor of PKC activity [14], has been shown
to mediate endothelial cell (EC) proliferation and abnormal vessel
formation in a rat model of retinopathy [15]. In addition to its well
known inhibitory effect on PKC, Riluzole also mediates other
signaling pathways including mGluR1-mediated glutamate release
[16,17] suggesting a role for mGluR1 in mediating angiogenesis.
Glutamate signaling occurs through binding to ionotropic or
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metabotropic receptors (mGluRs). mGluRs (genes: GRM1-GRM8;
protein receptors: mGluR1-mGluR8) belong to the family of G-
protein-coupled seven transmembrane domain receptors (GPCRs)
[18], which mediate responses to a diverse array of signaling
molecules, including hormones, neurotransmitters and chemo-
kines which can act in an autocrine or paracrine manner [19–22].
In the mammalian CNS, mGluRs are categorized into either
group I, II, or III receptors based on sequence homology, agonist
selectivity, and effector coupling. They are essential for normal
neuronal function and have been implicated in a wide range of
neurological disorders including amyotrophic lateral sclerosis
(ALS) [23–25], Parkinson’s disease [26], and depression [27], in
addition to various cognitive disorders [26]. mGluR1 and
mGluR5 comprise Group I and are mainly involved in excitatory
responses induced by strong presynaptic stimulation [28–30].
They are coupled to a Gaq-like protein and activate signaling
cascades known to be involved in proliferation [27,31]. In
addition, group I mGluR activation modulates a variety of ion
channels including the L-type voltage dependent calcium channels
[32–34] and activates a wide range of protein kinase pathways
(PKA, CaMKs, MAKs, PI3K) which link mGluRs to transcrip-
tional changes within a cell [27,31,34,35]. Within the past decade,
mGluR expression, in particular that of mGluR1, has been
detected in brain endothelial cells where mGluRs appear to play a
protective role in response to various insults such as hypoxia,
glutamate, and NO-induced vascular injury [36,37]. Based on
these studies and our recent finding demonstrating inhibition of
tumor progression by Riluzole and the mGluR1 inhibitor, BAY36-
7620 [38], we hypothesize that mGluR1 activity may play a key
role in regulating EC phenotype during tumor-induced angiogen-
esis and therefore might represent a molecular target for the
antiangiogenic therapy of cancer. In this paper, we test this
hypothesis and demonstrate that a loss of mGluR1 expression and
activity is associated with an anti-angiogenic phenotype and tumor
suppression.
Materials and Methods
Reagents and cell culture
All EC culture reagents and human dermal microvascular
endothelial cells (HDEC) were purchased from Lonza (Walkers-
ville, MD). Primary human umbilical vein endothelial cells
(HUVEC) and human pulmonary microvascular endothelial cells
(HLEC) were purchased from ScienCell Research Laboratories
(San Diego, CA). The immortalized human dermal microvascular
endothelial cell line (HMEC-1) was obtained from the Centers for
Disease Control and cultured as described [39]. All ECs were
cultured in their respective EGM-2 medium (basal medium)
containing the appropriate supplements and 10% serum which
were all purchased from Lonza and primary ECs were only used
for experimental analyses up to ten passages. The mouse
mammary carcinoma cell line 4T1-12B was a kind gift from Fred
Miller (Karmanos Cancer Institute) and MDA-MB-231 cells were
purchased from ATCC. Both cell lines were maintained in RPMI
containing 10% serum and 1% penicillin/streptomycin purchased
from Invitrogen-Life Technologies (Carlsbad, CA).
Reagents for immunohistochemical analysis, including second-
ary antibodies, were purchased from either Vector Laboratories
(Burlingame, CA) for sponge sections or from Santa Cruz (Santa
Cruz, CA) for tumor sections. mGluR1 inhibitors BAY36-7620
and YM 298198 were purchased from Tocris (Norwich, UK), and
research grade Riluzole was purchased from Sigma-Aldrich (St.
Figure 1. mGluR1 and GRM1 expression in various human vascular endothelial cells. A. mGluR1protein was detected by Western analysis
in primary human dermal microendothelial cells (HDEC), human umbilical vein endothelial cells (HUVEC), human lung microendothelial cells (HLEC),
as well as in the human microendothelial cell line (HMEC-1). Human brain lysate or MDA-MB-231 (MDA231) cells overexpressing GRM1 by Lentiviral
transduction were used as a positive control for mGluR1 and GAPDH was used as a loading control. B. Combined density graph of (A), normalized to
their respective GAPDH controls. C. GRM1 message was detected in HDEC, HUVEC, HLEC, and HMEC-1 by qPCR and normalized using GAPDH as the
reference gene. GRM1 message is detected in all ECs tested, comparable to levels detected in the breast cancer cell line (SUM159). These results
represent the mean 6 SEM of two experiments, performed in triplicate where * is p,0.05 compared to HDEC, HLEC, or HMEC-1.
doi:10.1371/journal.pone.0088830.g001
mGluR1 and Angiogenesis
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Louis, MO). Antibody against mGluR1 was purchased from
Millipore (Temecula, CA) and antibodies against human and
mouse CD31 were purchased from Abcam (Cambridge, MA) and
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), respectively.
Western analysis reagents were purchased from Bio-Rad (Hercu-
les, CA) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was purchased from Invitrogen-Life Technolo-
gies.
mGluR1 Protein Expression
mGluR1 expression in ECs was measured by Western blot
analysis. Briefly, cells were collected by scraping in RIPA lysis
buffer (Santa Cruz) containing 10 mM Tris-HCl, 1% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide,
and supplemented with a protease inhibitor cocktail solution. 75–
100 ug of protein was separated by SDS-polyacrylamide gel
electrophoresis (4–20%) and transferred to polyvinylidene fluoride
membranes. Immunodetection of mGluR1 was performed using
either rabbit polyclonal anti-mGluR1 antibody (Millipore) or
mouse monoclonal anti-mGluR1 antibody (BD Biosciences,
Bedford, MA) with appropriate secondary antibodies and detected
by chemiluminescence. Primary blots were stripped and reprobed
with antibody against GAPDH (Novus Biologicals, Littleton, CO).
RT-QPCR analysis of GRM1 expression
Total RNA was extracted from ECs using RNeasy Plus Mini
Kit (Qiagen, Valencia, CA) according to manufacturer instruc-
tions. Reverse transcription was performed with 2 ug RNA using
High-capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems-Life Technologies) according to the manufacturer’s instruc-
tions. QPCR was performed using ABsolute QPCR SYBR Green
Mix (Thermo Scientific) and oligonucleotide primers for GRM1
and GAPDH, as described previously [40]. Thermal cycling was
performed under the following conditions: 15 min enzyme
activation step at 95uC followed by 35 cycles of denaturation
(15 sec at 95uC), annealing (30 sec at 60uC), and extension (30 sec
at 72uC). No-RT controls were used to confirm lack of
contaminating genomic DNA.
GRM1 transduction assays
Lentiviral particles containing GRM1 shRNA vectors or non-
silencing control vector DNA (Thermo Scientific-Open Biosys-
tems), were generated by reverse transfection of these constructs,
together with Trans-Lentiviral package mix, into HEK293T cells
using Arrest-In/Express-In transfection reagent. Approximately
106 TU/ml was used to infect HUVEC in the presence of
polybrene (10 ug/ml) and a stable culture was generated by
growing these cells in the presence of 1 ug/ml puromycin, the
lowest concentration observed to kill 100% of non-transduced
HUVECs (data not shown). All reagents for these transduction
assays were purchased from Thermo Scientific.
Figure 2. Inhibition of cell proliferation by mGluR1 antagonists. Human dermal microendothelial cells (HDEC), human umbilical vein
endothelial cells (HUVEC), human lung microendothelial cells (HLEC) and the human microendothelial cell line (HMEC-1) were plated at 16105 cells/
well into 96-well plates in EBM-2 basal medium (no supplements) in reduced serum (5%) containing 100 ug/ml VEGF and exposed to various mGluR1
antagonists, or vehicle (0.05% DMSO). Cell proliferation was determined on day 3 by MTT assay where formazan product was detected by measuring
absorbance at 540 nm and results expressed as % control (no VEGF) where no growth was demonstrated. Both Riluzole (A) and BAY36-7620 (B)
significantly inhibited cell proliferation in a dose-response manner in all EC types whereas YM 298198 (C) had a significant effect on cell proliferation
in all the cell types except HUVEC. Results are the mean 6 SEM of three experiments, performed in triplicate, where * is p,0.05 compared to their
respective control cells containing VEGF.
doi:10.1371/journal.pone.0088830.g002
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Cell Proliferation
To determine a role for mGluR1 signaling on cell growth,
various ECs were plated at 16105 cells/well into 96-well plates in
EBM-2 basal medium (no supplements) in reduced serum (5%)
plus 100 ng/ml VEGF (R&D systems, Minneapolis, MN) and
exposed to various mGluR1 inhibitors, or vehicle (0.05% DMSO).
Proliferation was determined once a day for three days by
measuring the conversion of water soluble MTT into an insoluble
formazan product. Briefly, 12 mM MTT (Invitrogen-Life Tech-
nologies) was added to the wells and allowed to incubate for 2–
4 hours at which time DMSO was added to the wells to lyse the
cells and dissolve the formazan. The formazan product was
detected by measuring absorbance at 540 nm and results
expressed as % of control (no VEGF) where no growth was
demonstrated. In some experiments, cell numbers were also
determined in parallel with the MTT assay by counting manually
on a hemacytometer. The results of the inhibitor studies were
confirmed in a second set of experiments using shGRM1-infected
HUVECs.
Endothelial tube formation assays
ECs were plated on reduced serum Matrigel basement
membrane matrix (BD Biosciences) at either 16105 cells/ml
(HUVEC) or 2.56105 cells/ml (HMEC-1) in 24 well plates and
incubated overnight in basal EGM-2 media containing FBS (1%),
VEGF (100 ng/ml) and in the presence and absence of increasing
concentrations of either BAY36-7620 or Riluzole. After 18–
24 hours, brightfield images (using a 46 objective), were taken to
capture the entire well (4 image fields/well) using a Nikon Eclipse
TE2000-U inverted microscope and the endothelial tubes formed
were counted using the Java-based image processing program
(ImageJ64) developed by the National Institutes of Health. Results
were expressed as the average tubes formed/field and compared to
vehicle treated cells (0.05% DMSO). The results of the inhibitor
studies were confirmed in a second set of experiments using
shGRM1-infected HUVECs.
Matrigel sponge model
Angiogenesis was measured in vivo using the Matrigel sponge
model originally developed by Dr. Nor at the University of
Michigan [40]. Briefly, porous poly-l-lactic acid (PLLA) sponges
were prepared by dissolving PLLA in chloroform to yield a 5%
solution and then 1.6 ml of this solution was combined with 2.3 g
of sodium chloride in a beaker pre-treated with silicone. The
chloroform was evaporated and the sponges formed were washed
5 times over a two-day period to remove the salt and stored under
vacuum suction until use. The day before implantation, the
sponges were cut into 1061061 mm thick squares and then
sterilized by soaking in 100% ethanol for 2 hours followed by 2
washes of PBS and then left overnight in PBS. On the day of
implantation, HDECs were resuspended in Matrigel basement
membrane matrix and EBM-2 medium with supplements and
10% FBS at a ratio of 1:1 and 36 ul containing 16106 cells were
placed on top of each sponge and allowed to soak in for a few
minutes. The sponges were placed into the flanks of 15 female
athymic nude (nu/nu) mice, aged between 6 and 8 weeks (Harlan
Figure 3. shRNA-mediated knockdown of GRM1 inhibits cell proliferation of HUVECs. Knockdown of GRM1 was accomplished by infecting
with GIPZ shRNA Lentiviral vectors containing a puromycin resistance gene and either shRNA constructs#1-5 against GRM1 or a non-silencing shRNA
construct (NS). Cells were selected with puromycin (1 ug/ml) for 10 days and GRM1 message (A) or mGluR1 protein levels (B) were determined by
QPCR or Western analysis, respectively. C. Density graph of (B) repeated twice and normalized to their respective GAPDH controls. D. The effect of
GRM1 knockdown on the proliferation of HUVECs was determined 10 days post-infection by MTT assay. The shGRM1 infected cells were plated 10
days after infection in 96-well plates at 16105 cells/well into 96-well plates in EBM-2 basal medium (no supplements) in reduced serum (5%) plus
100 ng/ml VEGF and cell proliferation was determined on day three. These results are representative of two GRM1 silencing experiments performed
in triplicate where * is p,0.05 compared to NS-infected VEGF-treated cells.
doi:10.1371/journal.pone.0088830.g003
mGluR1 and Angiogenesis
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Laboratories, Indianapolis, IN), divided into groups of 5 and
treated i.p. starting the next day with either BAY36-7620 (10 mg/
kg), Riluzole (18 mg/kg) or vehicle (DMSO). Treatment contin-
ued once a day for 14 days at which time the mice were
euthanized and the sponges removed and placed in 10% formalin
for vessel analysis. Animals were housed in a pathogen-free facility
and all animal studies were performed in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the local IACUC at Wayne State
University School of Medicine, Detroit, MI (Protocol Number: 03-
03-11). Surgery was performed using carprofen analgesic and
under ketamine/xylazine anesthesia and all efforts were made to
minimize suffering.
Syngeneic breast tumor model
4T1 cells (36104) were injected into the #4 mammary fat pads
of female BALB/c mice, aged between 6 and 8 weeks old (Harlan
Laboratories), and allowed to grow for 10 days at which time small
tumors had begun to grow (average size of 62 mm3). Mice were
then divided into groups of 10 and treated with daily i.p. injections
of Riluzole (18 mg/kg), Sunitinib (20 mg/kg), or vehicle (DMSO)
for 14 days. Tumor size was measured two to three times a week
using a Vernier caliper and tumor volume was calculated using the
following formula: length 6 width 6 depth/2. Animals were
housed in a pathogen-free facility and all animal studies were
performed in accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the local
IACUC at Wayne State University School of Medicine, Detroit,
MI (Protocol Number: 03-02-11).
Immunohistochemistry
Sponges and tumor samples were placed in 10% formalin,
paraffin-embedded and sectioned. To stain, sections were first
deparaffinized using two changes of xylene for 3 minutes and
rehydrated through a graded series of ethanol (100%, 95%, 70%,
50%) to water. Sodium citrate was used for antigen retrieval and
sections were blocked in 5% serum from the host of the secondary
antibody. Microvessel density was determined by incubating
sections in either rabbit polyclonal anti-CD31 (Abcam) for sponge
sections or goat polyclonal anti-CD31 (Santa Cruz) for tumor
sections followed by incubation in the appropriate FITC-
conjugated secondary antibodies. Slides were cover-slipped using
SlowFade Gold antifade reagent with DAPI (Invitrogen) and
examined on a Nikon Ti E-Series inverted microscope. Fluores-
cent images were captured under identical conditions where
fluorescent intensity was adjusted to exclude background signal
from the isotype-containing secondary antibody. Sponges were
evaluated for vessel formation by immunofluorescence where
CD31-expressing vessels were counted and averaged. In this
angiogenic model, vessels are not homogenously distributed
throughout the sponges. Instead, they occur in groupings or
‘‘hotspots’’ with at least 5 hotspots occurring per treatment slide.
Therefore, to interpret the effect of Riluzole and BAY36-7620 in
this model, vessels were counted in 5 hotspot fields per slide (2
slides per animal) using ImageJ64 and results expressed as the
average number of vessels per field (2006). Tumors were
Figure 4. Riluzole and BAY36-7620 inhibit endothelial tube formation on Matrigel. HUVEC and HMEC-1 were plated onto Matrigel coated
24 well plates at 26105 cells per well and incubated overnight in the presence of medium containing FBS (1%), VEGF (100 ng/ml) and either 0
(vehicle), 10, 25, or 50 uM Riluzole or BAY36-7620 (BAY) after which cells were photographed and the number of tubes per 46field were counted and
averaged. Both Riluzole (A) and BAY (B) inhibited tube formation in HUVECs in a dose-dependent manner compared to vehicle (DMSO) treated cells.
C and D represent the results of two experiments performed in triplicate in HUVECs and HMEC-1, respectively where * is p,0.05 compared to vehicle
(DMSO) treated cells.
doi:10.1371/journal.pone.0088830.g004
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PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e88830
evaluated for microvessel density by counting and averaging the
number of vessels per tissue area (mm2) using ImageJ64. CD31
stained cells were considered a vessel when a structure contained
more than 2 CD31 positive-stained cells and structures that
formed parts of the same vessel were counted as a single vessel.
Statistical analysis
Data were analyzed using GraphPad Prism version 4 for
Macintosh (GraphPad Software, San Diego, CA). All numerical
results are expressed as mean 6 SEM and statistical analysis was
performed by either one-way or two-way repeated-measures
analysis of variance (ANOVA) followed by a multiple comparison
procedure with the Student-Newman Keuls method. A value of #
0.05 was considered significant.
Results
mGluR1 is expressed in human endothelial cells and
regulates cell proliferation
To determine whether mGluR1 is expressed in human ECs, we
assessed several primary ECs (HDEC, HUVEC, HLEC) or cell
lines (HMEC-1) for mGluR1 by Western blot analysis. mGluR1
was detected in all four EC types with higher levels expressed in
HUVEC and HMEC-1 (Fig. 1A–B). However, these levels were
not significantly different from each other. These results were
similar to GRM1 QPCR results where GRM1 expression levels
were demonstrated in all ECs tested with significantly higher levels
demonstrated in HUVEC (Fig 1C). Using these ECs we assessed
cell proliferation in the presence of the mGluR1 non-competitive
antagonists BAY36-7620 and YM298198, as well as Riluzole, at
various concentrations for up to 3 days. BAY36-7620 and
YM298198 are specific antagonists of mGluR1 that exhibit their
effect through direct association with the receptor [41,42].
Riluzole, in addition to inhibiting mGluR1, has been shown to
affect other signaling pathways as well, including but not limited to
calcium release, PKC, and voltage-gated sodium channels [43].
We chose to test Riluzole despite its significant off-target effects
because, unlike BAY36-7620 and YM298198, Riluzole is FDA-
approved for another indication, amyotropic lateral sclerosis, and
could therefore be rapidly translated to clinical trials through off-
label use as an antiangiogenic agent. In addition, Riluzole shows
minimal toxicity with long-term oral administration [44]. Both
Riluzole and BAY36-7620 significantly inhibited cell proliferation
in all the ECs tested compared to vehicle treated control cells
containing VEGF (Fig. 2). Both HUVEC and HMEC-1 were the
most sensitive to inhibition by either Riluzole (85% and 70%,
respectively) or BAY36-7620 (90% and 91%, respectively) at the
highest concentration tested, which is not surprising given that
they express the highest level of mGluR1 protein (Fig. 1).
YM298198 was also able to inhibit cell proliferation of all ECs
tested, however, this effect was not as robust and was only
significant in three of the ECs, excluding HUVECs. Since
Figure 5. shRNA-mediated knockdown of GRM1 inhibits endothelial tube formation on Matrigel. HUVECs, in which the GRM1 gene was
silenced using GIPZ shGRM1 Lentiviral vectors 1–5 or a non-silencing vector (NS) as described previously (Fig. 3 and Methods section), were plated
onto Matrigel at 26105 cells per well and incubated overnight in the presence of medium containing FBS (1%) and VEGF (100 ng/ml). After overnight
treatment, cells were photographed (A) and the number of tubes formed per 46field were counted using ImageJ64 software and averaged (B). Tube
formation on the Matrigel was significantly inhibited in the HUVECs infected by all the shGRM1 vectors when compared to HUVECs infected with the
NS vector. Results are representative of two experiments performed in triplicate where * is p,0.01 and # is p,0.05 compared to NS-infected cells.
doi:10.1371/journal.pone.0088830.g005
mGluR1 and Angiogenesis
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HUVEC express the highest level of mGluR1, these results suggest
YM298198 to be a weaker antagonist of mGluR1 compared to
Riluzole or BAY36-7620.
To confirm a role for mGluR1 in mediating cell proliferation,
HUVECs were transduced with Lentiviral vectors expressing one
of five GRM1 silencing shRNAs or a non-silencing control vector
(NS) and after which they were stably selected using puromycin
(1 ug/ml) and then cell proliferation was measured. According to
Western and QPCR analysis, ten days after infection, both
mGluR1 protein levels and GRM1 message were inhibited in all
shGRM1-infected cells compared to NS vector-treated cells
(Fig. 3A–C). GRM1 message was significantly inhibited by a
maximal 60–75% in the HUVECs infected with all the shGRM1
vectors except # 2 (Fig. 3A). Interestingly, there was a strong
association between the potency of vectors #3-5 at knocking down
GRM1 message with its ability to inhibit mGluR1 protein
expression (Fig. 3B–C). Cell proliferation, which was assessed 10
days post-infection, was significantly inhibited in all the shGRM1-
silenced cells with maximal inhibition averaging around 50%,
compared to the NS VEGF-treated cells (Fig. 3D).
mGluR1 regulates Matrigel tube formation in HUVEC and
HMEC-1
To assess whether mGluR1 mediates angiogenesis, we mea-
sured the effect of Riluzole and BAY36-7620 on tube formation by
HUVECs and HMEC-1 cells when plated on serum-reduced
Matrigel in the presence of VEGF. We chose these two inhibitors
because of their ability to inhibit cell proliferation in these cells.
The ability of HUVEC (Fig 4A–C) and HMEC-1 (Fig. 4D) to form
tubes on Matrigel was significantly inhibited in a dose-response
manner by Riluzole (48% and 60%, respectively) and BAY36-
7620 (98% and 96%, respectively) at the highest concentrations
tested. Interestingly, BAY36-7620, which is a more specific
inhibitor of mGluR1, demonstrated a greater inhibitory effect on
tube formation than Riluzole in both HUVECs and HMEC-1
cells. These results suggest that mGluR1 plays a role in mediating
the angiogenic process. To further confirm this role, we repeated
the Matrigel tube formation assay using the same shRNA-infected
HUVECs as described above (Fig. 5A). Tube formation was
significantly inhibited in all the shGRM1-infected cells when
compared to NS-infected control, with a maximal inhibitory effect
of approximately 35% in all the shGRM1-infected cells except #3
(Fig. 5B). All of the tube formation experiments were performed in
the presence of low serum (1%) and 100 ug/ml VEGF (required
for tube formation) and MTTs were performed in parallel to
confirm any possible effect of cell growth on tube formation.
mGluR1 inhibits the angiogenic process in vivo
To determine whether mGluR1 can mediate angiogenesis in
vivo, we utilized the Matrigel sponge model originally developed
by Nor and Polverini [40]. Matrigel-containing human dermal
microendothelial cells were seeded into porous matrices (sponges)
and implanted subcutaneously into the flanks of immunodeficient
(nude) mice, which were then treated with Riluzole, BAY36-7620,
or vehicle (DMSO). After two weeks of treatment, when maximum
vessel formation is known to occur [40], the sponges were
harvested and the vessels stained with CD31 to visualize for
counting. Even though vessel count was relatively low, we were
able to detect a significant reduction in the number and size of the
vessels formed in the sponges from the inhibitor-treated mice
compared to the vehicle-treated mice. In the sponges from both
the Riluzole and BAY36-7620 treated mice, vessel formation was
inhibited by approximately 50% when compared to the vehicle-
treated mice (Fig. 6).
Figure 6. Riluzole and BAY36-7620 (BAY) inhibit angiogenesis in a Matrigel sponge assay. Polylactic sponges containing 16106 human
dermal microendothelial cells were implanted subcutaneously into the flanks of athymic nude (nu/nu) mice. The next day, dosing i.p. with Riluzole
(18 mg?kg21?d21) or BAY (10 mg?kg21?d21) was begun and continued for 2 weeks before harvesting. A. Vessels were identified by immunostaining
using anti-CD31 antibody (green) and counterstained with DAPI (blue). Arrows indicate an average size vessel in each group. B. The number of CD31-
expressing vessels in 5 hotspot fields per slide (2 slides per animal) was determined using ImageJ64 and the results expressed as the average number
of vessels per field. Both Riluzole and BAY significantly inhibited vessel formation by approximately 50% compared to vehicle (DMSO) treated animals
where * is p,0.05 compared to vehicle treated mice and n=5 mice per treatment group.
doi:10.1371/journal.pone.0088830.g006
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Recently, we have discovered that mGluR1 is expressed and
active in breast cancer cells and that Riluzole, at doses equivalent
to doses already being used clinically in humans to treat ALS, can
significantly inhibit the growth of breast tumor xenografts [38].
Since angiogenesis is known to play an important role in the
development and progression of breast cancer, we wanted to
estimate the extent to which Riluzole can inhibit the angiogenic
process in breast tumors. To test this, we used the 4T1 syngeneic
murine mammary tumor model because this model has been
demonstrated to have a strong vascular component [45,46]. We
injected 4T1 cancer cells into the mammary fat pads of mice and,
7 days after injection, started dosing the mice with Riluzole,
Sunitinib, a known inhibitor of angiogenesis, or vehicle (DMSO).
Similar to its effect on tumor progression in the MDA231
xenograft model, Riluzole was able to inhibit tumor progression in
the 4T1 model, significantly inhibiting growth by approximately
50% as early as day 9 compared to the vehicle-treated tumors
(Fig. 7A). As expected, Sunitinib had a similar effect on tumor
growth, significantly inhibiting tumor growth by approximately
50% that reached significance by day 14. By CD31 staining, we
were able to visualize the vessels in the tumors from these mice
(Fig. 7B–C). Even though vessel count was relatively low in the
tumors from the vehicle-treated mice (Fig. 7C), there was a
significant reduction in microvessel density demonstrated in both
Riluzole and Sunitinib-treated mice. Microvessel density in both
the Riluzole and Sunitinib-treated tumors was inhibited by
approximately 60% and 80%, respectively compared to vehicle-
treated tumors (Fig. 7C). This result suggests that Riluzole, in
addition to its direct effect on tumor cell growth [38], might
mediate tumor progression through its inhibitory effect on the
angiogenic process. Further experiments will be required to
determine the relative importance of the antiangiogenic effect of
Riluzole compared to its direct effect on ECs or an indirect effect
through its action on tumor cells (e.g., inhibiting the release of pro-
angiogenic factors).
Discussion
In this study, we detected expression of mGluR1 by ECs and,
using pharmacological inhibitors and gene silencing, demonstrate
a novel role for mGluR1 in mediating various steps of the
angiogenic process including EC proliferation, Matrigel tube
formation and vessel formation in vivo. To our knowledge, this is
the first study in which mGluR1 has been shown to play a role in
mediating the angiogenic process. In a previous study, Riluzole
was shown to inhibit VEGF-stimulated EC proliferation and vessel
formation in a rat model of ROP, mediating its effect through
PKC [15]. Although Riluzole is widely known to inhibit glutamate
release [16,17], it does not act directly on glutamate receptors.
Rather, it is thought to indirectly inhibit glutamatergic signaling,
either through inhibition of glutamate release through its action on
ion channels or through its ability to inhibit downstream mediators
and targets of mGluR1, such as PKC [14], voltage gated sodium
and calcium channels [43,47].
In the present study, mGluR1 gene silencing resulted in
endothelial growth inhibition and reduced vessel formation,
suggesting a role for mGluR1 as a mediator of angiogenesis.
Figure 7. Riluzole inhibits tumor growth and reduces microvessel density in the 4T1 syngeneic breast tumor model. 4T1 breast cancer
cells (36104) were injected into the mammary fat pad of BALB/c mice. Treatment with either Riluzole (18 mg?kg21?d21), Sunitinib (20 mg?kg21?d21),
or vehicle (DMSO) was initiated in established tumors (62 mm3) on day 10 post tumor cell injection and continued for 14 days. Tumor volumes were
measured two or three times weekly and mean tumor volume 6 SEM was determined (A). * is p,0.05 and n= 10 mice per treatment group. B.
Tumor sections analyzed for microvessel density by immunofluorescent staining using anti-CD31 antibody (green) and counterstained with DAPI
(blue) (10006). C. When compared to vehicle-treated mice, microvessel density was significantly inhibited in both the Riluzole and Sunitinib- treated
mice. Microvessel density was determined by counting and averaging the number of vessels per tissue area (mm2) per slide using ImageJ64 (1006
magnification) and as described previously (Methods section) where * is p,0.05 compared to vehicle-treated mice and n= 10 slides per treatment
group.
doi:10.1371/journal.pone.0088830.g007
mGluR1 and Angiogenesis
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e88830
mGluR1 is a member of the Group I mGluR family which, being
GPCRs, are primarily coupled to the activation of Gaq/11
proteins which stimulate the PLCb pathway, resulting in the
cleavage of phosphatidylinositol-4,5-bisphosphate into inositol-
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [27,31,34].
Both DAG and IP3 (by stimulating release of calcium from
intracellular stores) activate PKC which has also been shown to
activate phospholipase D, phospholipase A2 as well as to modulate
a variety of ion channels [32,33]. Since the angiogenic process is
highly dependent on VEGF and PKC is a downstream mediator
of VEGF activity, it is possible that PKC acts as a coincidence
detector, whereby both VEGF and mGluR1 activity are required
for its full activation. Indeed, in a previous study in melanoma
cells, stimulation of mGluR1 activated PKC epsilon and ERK1/2
[48] suggesting that this isoform may be involved in mediating
mGluR1 effects in endothelial cells as well. In addition to PKC,
stimulating group I mGluRs in various neuronal populations
activates other protein kinases as well, including cAMP dependent
protein kinase (PKA), calcium calmodulin-dependent protein
kinases (CaMKs), mitogen-activated protein kinases (MAPKs),
phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin
(mTOR), p70 S6 kinase, casein kinase 1, and cyclin-dependent
protein kinase 5 [26,27,33,34,49–52]. In addition, the PKA,
CaMKs, MAPKs, and PI3K pathways have been shown to link
group I mGluRs to transcriptional changes as well [27,31,35].
Therefore, whether mGluR1 is capable of mediating the
angiogenic process by modulating VEGF activity, or indepen-
dently, through activation of other protein kinase pathways
including PKA, CaMKs, MAPKs, or PI3K, or both, is unknown
and is the current focus of our lab.
We have previously identified mGluR1 receptors in triple
negative breast cancer cells and have demonstrated that inhibiting
mGluR1 activity with BAY36-7620 or Riluzole, at doses
equivalent to doses already being used clinically in human beings
to treat ALS, significantly inhibits the growth of MDA-MB-231
xenografts in mice [38]. In the current study, we have also
observed that inhibiting mGluR1 activity with Riluzole signifi-
cantly inhibits the growth of 4T1 tumors and also results in
reduced vessel formation, suggesting that mGluR1 can inhibit
angiogenesis within the tumor microenvironment. Therefore, it is
plausible that mGluR1 plays a dual role in TNBC, both in the
tumor compartment, where it directly stimulates tumor cell
growth, and in the tumor microenvironment, where it stimulates
angiogenesis. The results of this study suggest that mGluR1
represents a promising molecular target in TNBC, an aggressive
type of breast cancer with a strong vascular component. Because
Riluzole is already an FDA-approved drug with low toxicity and
few side effects, the repurposing of Riluzole for the treatment of
TNBC may represent a promising therapeutic strategy. It is not
difficult to envision using Riluzole in combination with conven-
tional therapy such as chemotherapy and radiation therapy, which
we have already shown to work in synergy with VEGF therapy in
various cancers [53] or in a role similar to aromatase inhibitors
and Tamoxifen in hormone-responsive breast cancers.
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